Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2015 (2015), Article ID 351431, 5 pages
Case Report

Lymphocyte-Predominant Hodgkin’s Disease in Children: A Case Study and Review of the Literature

1Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA 70112, USA
2Department of Pediatrics, Ochsner Health System, New Orleans, LA 70112, USA
3Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA 70112, USA
4Department of Pediatric Hematology-Oncology, Ochsner Health System, New Orleans, LA 70121, USA
5University of Queensland School of Medicine, Brisbane, QLD 4006, Australia

Received 2 January 2015; Revised 26 February 2015; Accepted 10 March 2015

Academic Editor: Nurdan Tacyildiz

Copyright © 2015 James R. Stier and Robert J. Vasquez. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


A three-year-old boy presented with an enlarging neck mass. Biopsy demonstrated IgD-positive nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), which was staged as IIa. The patient received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with rituximab and had excellent results. NLPHL is a relatively rare disease that is biologically distinct from classic Hodgkin lymphoma (cHL). NLPHL is a B-cell malignancy likely of germinal center origin that has an overall good prognosis and favorable response to treatment. Unlike cHL, NLPHL is ubiquitously CD20-positive. Recent evidence supports the efficacy of targeted anti-CD20 therapy in NLPHL, though prospective data is limited. This case demonstrates several unique features of NLPHL and further supports the use of rituximab in front-line therapy. The clinical characteristics among patients at various ages are discussed with a special focus on the IgD-positive subtype. A thorough literature search demonstrates this to be the youngest patient with NLPHL yet described.